Banker Accused in $41M Biotech Insider Trading Scheme, SEC Probes Deepen

• Wall Street Wolf in Biotech Sheep's Clothing: Ex-Citibank banker and five cronies charged in a jaw-dropping $41M insider trading and manipulation racket targeting cancer and opioid drug stocks.
• Fake It Till You Make It... Rich: Crooks allegedly cooked up bogus clinical data and press releases to rocket shares of Olema Oncology ($OLMA) and Opiant Pharmaceuticals ($OPNT).
• SEC Sniffs Blood: Probes intensify on leaked M&A secrets from AbbVie, GSK, and Pfizer deals, with more indictments looming in this pharma plot twist.

Hold onto your stock certificates, scandal-hunters! In a plot twist juicier than a Netflix docuseries, the SEC and DOJ just unleashed hell on a sly squad of six schemers, headlined by a former Citibank investment banker who's now the poster boy for "betraying the boardroom." We're talking a $41 million biotech bonanza built on whispers of secret mergers, phony press pops, and data faker than a politician's promise.

Picture this: Our anti-hero banker, straight out of the glossy towers of Citi (and whispers of Lazard ties), spills the beans on blockbuster buyouts. AbbVie, GSK, Pfizer—you name the pharma behemoth, their M&A tea got spilled to the tune of tens of millions in illicit gains. But these foxes didn't stop at tipping; they went full mad scientist, fabricating "positive" trial results and hype releases to spike stocks like Olema Oncology's cancer fighter and Opiant's opioid antidote. Shares soared, suckers bought in, and the crew cashed out fatter than a venture capitalist's ego.

The feds' December 22 smackdown, fresh as yesterday's latte, accuses the banker, a Forbes 30-under-30 tech darling turned co-conspirator, and four other inside players of a multi-year pump-and-dump party. "This was no victimless crime," boomed SEC enforcers in their filing, as if we needed reminding—retail investors got fleeced while these geniuses toasted with Dom Pérignon.

But wait, the plot thickens faster than clotting agents! SEC probes are "deepening," per Bloomberg Law and FierceBiotech reports, sniffing around a web of global tippers from France to Singapore (echoes of that November global ring bust). Is this the tip of a tainted pipette? Biotech Twitter's ablaze—posts from insiders like Kristen Shaughnessy and BioStocks scream "more to come," with tickers like $IMMU, $FPRX, and $GBT in the crosshairs.

The banker's defense? Crickets so far, but expect the classic "rogue actor" spin. Meanwhile, victims lick wounds from manipulated markets, and the SEC's insider trading hit list grows longer than a CVS receipt. Moral of this pharma fiasco? In biotech, where hope trades at a premium, trust no one—not even the suit with the golden Rolodex.

Stay tuned, traders—this SEC safari's just revving up. Who’s next on the chopping block? Your portfolio’s praying it ain’t you.